Laboratory and genetic predictors for severe COVID-19 infection

被引：0

作者：

Kadiyska, Tanya ^{[1
,2
]}

Cherneva, Radostina ^{[3
]}

Cherneva, Zheina ^{[4
]}

Marchev, Sotir ^{[4
]}

Madzharova, Dilyana ^{[2
]}

Tourtourikov, Ivan ^{[2
,5
]}

Mitev, Vanyo ^{[5
]}

机构：

[1] Med Univ Sofia, Dept Physiol & Pathophysiol, Sofia, Bulgaria

[2] Genica & Genome Ctr Bulgaria, Genet Med Diagnost Lab, Sofia, Bulgaria

[3] Univ Hosp Resp Dis St Sophia, Sofia, Bulgaria

[4] Minist Internal Affairs, Med Inst, Clin Cardiol, Sofia, Bulgaria

[5] Med Univ Sofia, Dept Med Chem & Biochem, Sofia, Bulgaria

来源：

PHARMACIA | 2024年 / 71卷

关键词：

COVID-19; OAS1; laboratory and genetic predictors; CLINICAL CHARACTERISTICS; CYTOKINE; WUHAN;

D O I：

10.3897/pharmacia.71.e120638

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This study aims to identify laboratory and genetic markers important for COVID-19 severity to improve patient assessment and treatment. COVID-19 patients were divided into two groups based on disease severity. Clinical, laboratory (complete blood count, complete biochemical parameters - lactate dehydrogenase (LDH), serum ferritin), and genetic markers (OAST rs4767027) were analyzed. A total of 61 COVID-19 patients and 48 negative controls were investigated. Group I showed more often lymphopenia - 3.16 (1.39-3.89) vs 5.61(4.21-7.98), p-0.027 and thrombocytopenia - 165 (75-256) vs 212 (198-349), p-0.031, higher LDH (621 +/- 218 U/L vs 312 +/- 110 U/L), p-0.014. OAS1 rs4767027 genotype and allele frequencies did not differ significantly from worldwide population frequencies. Lymphopenia and thrombocytopenia are likely associated with immune inflammation and COVID-19 severity. While increased OAS1 transcript levels are correlated with reduced risk of infection, they can contribute to NLRP3 inflammasome activation once the infection has been established.

引用

页码：1 / 8

页数：8

共 50 条

[31] Genetic risk factors for severe COVID-19
Bottcher, S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 31 - 31
[32] COVID-19 infection in infant with severe CHD
Pexton, Natalie
Svenson, Amy
Bhat, Deepti
CARDIOLOGY IN THE YOUNG, 2021, 31 (10) : 1704 - 1705
[33] Hematopoietic memory of severe COVID-19 infection
Anaisa V. Ferreira
Mihai G. Netea
Cell Research, 2024, 34 : 187 - 188
[34] Mild versus severe COVID-19: Laboratory markers
Velavan, Thirumalaisamy P.
Meyer, Christian G.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 : 304 - 307
[35] Severe scald injury in a patient with severe COVID-19 infection
Stoegner, V-A
Dieck, T.
Vogt, P. M.
Krezdorn, N.
ANASTHESIOLOGIE & INTENSIVMEDIZIN, 2021, 62 : 522 - 526
[36] GENETIC PREDICTORS OF SEVERITY AND EFFICACY OF COVID-19 PHARMACOTHERAPY
Shishimorov, I. N.
Magnitskaya, O., V
Ponomareva, Yu, V
PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA, 2021, 9 (03): : 174 - 184
[37] Inflammatory markers as predictors of mortality in COVID-19 infection
Ahmeidi, Awadia A.
Musa, Ashraf
Ahmed, Hend S.
Elahmar, Adel A.
Goota, Ryhana B.
Ahmed, Ibtihal A.
Ali, Abdelhakam H.
Allam, Mushal
Hassan, Mozan O.
AFRICAN JOURNAL OF LABORATORY MEDICINE, 2020, 9 (01)
[38] Genetic predisposition models to COVID-19 infection
Darbeheshti, Farzaneh
Rezaei, Nima
MEDICAL HYPOTHESES, 2020, 142
[39] Genetic Polymorphisms in the Host and COVID-19 Infection
Delanghe, Joris R.
De Buyzere, Marc L.
Speeckaert, Marijn M.
CORONAVIRUS DISEASE - COVID-19, 2021, 1318 : 109 - 118
[40] Genetic variability in the case of COVID-19 infection
Cammarata-Scalisi, Francisco
Tadich, Antonio Cardenas
Callea, Michele
ARCHIVOS ARGENTINOS DE PEDIATRIA, 2020, 118 (05): : 304 - 305

← 1 2 3 4 5 →